E Fund Management Co. Ltd. Makes New Investment in IQVIA Holdings Inc. $IQV

E Fund Management Co. Ltd. bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,192 shares of the medical research company’s stock, valued at approximately $424,000.

A number of other hedge funds and other institutional investors have also modified their holdings of IQV. Vanguard Group Inc. increased its stake in shares of IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after buying an additional 159,899 shares during the period. BlackRock Inc. acquired a new position in shares of IQVIA during the second quarter valued at $2,811,292,000. Geode Capital Management LLC boosted its holdings in IQVIA by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after acquiring an additional 24,453 shares during the last quarter. Boston Partners increased its position in IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after purchasing an additional 530,672 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in IQVIA by 16.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after purchasing an additional 528,753 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on IQV shares. William Blair raised shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Royal Bank Of Canada raised their price objective on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. Finally, Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Price Performance

IQVIA stock opened at $256.66 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $42.25 billion, a P/E ratio of 31.84, a PEG ratio of 2.12 and a beta of 1.18. The business has a 50-day moving average of $211.74 and a 200-day moving average of $187.01. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $260.30.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period last year, the company posted $2.81 EPS. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has approved a share buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.